Kazia Therapeutics Ltd
KZIA9.790USD
0.000
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
32.59MValor de mercado
--P/L TTM
Mais detalhes de Kazia Therapeutics Ltd Empresa
Kazia Therapeutics Limited is an oncology-focused drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.
Informações da empresa
Código da empresaKZIA
Nome da EmpresaKazia Therapeutics Ltd
Data de listagemSep 01, 1994
Fundado em1994
CEODr. John E. Friend, M.D.
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalSep 01
EndereçoThree International Towers Level 24,
CidadeSYDNEY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísAustralia
Código postal2000
Telefone1161298780088
Sitehttps://www.kaziatherapeutics.com/
Código da empresaKZIA
Data de listagemSep 01, 1994
Fundado em1994
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Anna Sandham
Ms. Anna Sandham
Company Secretary
Company Secretary
--
--
Dr. John E. Friend, M.D.
Dr. John E. Friend, M.D.
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
Interim Executive Chairman of the Board, Chief Executive Officer, Managing Director
--
--
Stephen Palmer
Stephen Palmer
Program Director - Degenerative Diseases
Program Director - Degenerative Diseases
--
--
Mr. Peng K. Leong, Ph.D.
Mr. Peng K. Leong, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Karen Krumeich
Ms. Karen Krumeich
Chief Financial Officer
Chief Financial Officer
--
--
Lilischkis Ron Kimberley
Lilischkis Ron Kimberley
Clinical & Regulatory Affairs Manager
Clinical & Regulatory Affairs Manager
--
--
Mr. Bryce Carmine
Mr. Bryce Carmine
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Justine R. Stehn, Ph.D.
Dr. Justine R. Stehn, Ph.D.
Director - ATM Program
Director - ATM Program
--
--
Mr. Steven Roy Stent (Steve) Coffey
Mr. Steven Roy Stent (Steve) Coffey
Non-Executive Director
Non-Executive Director
--
--
Ms. Ebru Davidson
Ms. Ebru Davidson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 4 de mar
Moeda: USDAtualizado em: ter, 4 de mar
FY2022
FY2021
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Sweden (Country)
0.00
0.00%
China (Country)
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 15 horas
Atualizado em: há 15 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Investidores
Investidores
Proporção
Chernett (Jorey)
10.09%
Barclays Capital Inc.
1.77%
UBS Financial Services, Inc.
0.39%
MAI Capital Management, LLC
0.06%
Rhumbline Advisers Ltd. Partnership
0.03%
Other
87.67%
Tipos de investidores
Investidores
Proporção
Individual Investor
10.09%
Research Firm
1.77%
Investment Advisor
0.43%
Investment Advisor/Hedge Fund
0.08%
Hedge Fund
0.02%
Other
87.62%
Participação acionária institucional
Atualizado em: ter, 4 de mar
Atualizado em: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
38
13.88K
1.02%
-25.51K
2024Q4
39
333.53K
5.24%
-391.82K
2024Q3
37
220.02K
0.81%
-322.92K
2024Q2
32
329.65K
0.99%
-162.64K
2024Q1
33
37.63K
1.43%
-462.76K
2023Q4
33
488.86K
18.54%
+447.75K
2023Q3
33
24.22K
1.03%
-36.82K
2023Q2
34
28.95K
1.27%
-34.22K
2023Q1
33
27.66K
1.21%
-46.04K
2022Q4
36
43.17K
2.64%
-48.21K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Barclays Capital Inc.
24.00K
0.38%
+24.00K
--
Dec 31, 2024
UBS Financial Services, Inc.
5.51K
0.09%
+520.00
+10.42%
Dec 31, 2024
MAI Capital Management, LLC
27.84K
0.44%
+564.00
+2.07%
Dec 31, 2024
Rhumbline Advisers Ltd. Partnership
556.00
0.01%
--
--
Dec 31, 2024
Armistice Capital LLC
1.10K
0.02%
+1.10K
--
Sep 30, 2024
Osaic Holdings, Inc.
100.00
0%
+90.00
+900.00%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Data
Tipo
Proporção
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Mar 06, 2025
Merger
5<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
Oct 15, 2024
Merger
10<1
